Relationship between body mass index and anti-hypertensive efficacy of doxazosin according to a survey of Japanese patients

Journal of International Medical Research

Volumn 32, Issue 2, 2004, Pages 176-184

  Toyonaga, S ^a   Nakatsu, T ^a   Suezawa, C ^b   Matsubara, H ^b   Sogou, T ^b   Kusachi, S ^c  

^a Kagawaken Saiseikai Hospital   (Japan)

^b TAKAMATSU RED CROSS HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Body mass index; Doxazosin; Hypertension; Obesity; Survey; 1 blockers

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARASEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; NIFEDIPINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; ORTHOSTATIC HYPERTENSION; OUTPATIENT DEPARTMENT;

EID: 1642569202     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200211     Document Type: Article

References (14)

1. Guidelines Subcommittee: 1999 World Health Organization: International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151 - 183.
2. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613 - 634.
3. Yoshiike N, Nishi N, Matsushima S, Itoh C, Ikeda Y, Kashihara H, et al: Relationship between body mass index and diabetes, hypertension, or hyperlipidemia of risk factor: A multicenter epidemiologic survey. Obes Study 2000; 6: 4 - 17.
4. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514 - 1520.
5. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173 - 194.
6. Hopkins PN, Hunt SC, Wu LL, Williams GH, Williams RR: Hypertension, dyslipidemia, and insulin resistance: Links in a chain or spokes on a wheel? Curr Opin Lipidol 1996: 7: 241 - 253.
7. Landsberg L: Insulin-mediated sympatRetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001; 19: 523 - 528.
8. Corica F, Corsonello A, Ientile R, De Gregorio T, Malara A, Artemisia A, et al: Leptin and norepinephrine plasma concentrations during glucose loading in normotensive and hypertensive obese women. Am J Hypertens 2001; 14: 619 - 626.
9. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, et al: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243 - 1252.
10. El-Gharbawy AH, Kotchen JM, Grim CE, Kaldunski M, Hoffmann RG, Pausova Z, et al: Gender-specific correlates of leptin with hypertension-related phenotypes in African Americans. Am J Hypertens 2002; 15: 989 - 993.
11. Saito I, Takeshita E: Morbidity of obese hypertension. Health Center Keio University 1987; 6: 22 - 26.
12. Lithell H: Insulin resistance and cardiovascular drugs. Clin Exp Hypertens A 1992; 14: 151 - 162.
13. Giorda C, Appendino M, Mason MG, Imperiale E, Pagano G: Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995; 44: 673 - 676.
14. Hozawa A, Ohkubo T, Kikuya M, Yamaguchi J, Ohmori K, Fujiwara T, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: The Ohasama study. Hypertens Res 2002; 25: 57 - 63.